David Parra, PharmD, FCCP, BCPS
Residency, Cardiovascular Pharmacotherapy, University of Minnesota
Fellowship, Cardiovascular Pharmacotherapy, University of Minnesota
PharmD, University of Minnesota
Bachelor of Biology, Marquette University
Licensures and Certifications
Dr. Parra received an undergraduate degree from Marquette University, and a Doctor of Pharmacy degree from the University of Minnesota where he subsequently completed a two-year postdoctoral residency and fellowship in cardiovascular pharmacotherapy. Dr. Parra is a Fellow of the American Heart Association and American College of Clinical Pharmacy. He currently is the Veterans Integrated Service Network 8 PBM Clinical Pharmacy Program Manager and Academic Detailer in Cardiology and Anticoagulation and has a practice site at the West Palm Beach Veterans Affairs Medical Center as a Clinical Pharmacy Specialist in the Department of Cardiology. He is also a clinical associate professor within the Department of Experimental and Clinical Pharmacology at the University of Minnesota College of Pharmacy.
Dr. Parra has over 90 official abstract presentations and publications and has presented research findings at the American Heart Association Scientific Sessions, European Society of Cardiology Congress, American Society of Hypertension, and other medical and pharmacy scientific forums. Dr. Parra served as co-chair of the American College of Cardiology (ACC) Scientific Sessions Pharmacology Sessions from 2010-2014, faculty of the ACC Core Curriculum 2016-2021, and served as a member of the American Heart Association’s Council on Clinical Cardiology Clinical Pharmacology Committee from 2017-2021. In addition, Dr. Parra has a significant interest in personalizing anti-hypertensive therapy utilizing impedance cardiography, biomarkers, and 24hr ambulatory blood pressure monitoring. He has several publications and presentations on the topic as well as being co-developer of an app (PRA and HTN) for smartphones to assist with this.
- Heart Failure
- Cardiovascular Pharmacothearpy
Awards & Recognition
- Under Secretary for Health Pharmacy Benefits Management Innovation Award 2019
- Fellow of the American Heart Association 2019
- University of Maryland School of Pharmacy 2011
- Francis S. Balassone Memorial Lecture Clinical Pharmacist of the Year-West Palm Beach Veterans Affairs Medical Center, 2010
- University of Minnesota College of Pharmacy Institutional Preceptor of the Year, 2008
- Special Contribution Award-Transplant Model of Care, Veterans Affairs Central Office, 2008
- University of Minnesota PDX Distinguished Alumnus, 2007
- Palm Beach Atlantic University College of Pharmacy-Distinguished Preceptor, 2007
- Palm Beach Atlantic University College of Pharmacy -Honorary Alumnus, 2007
- University of Minnesota College of Pharmacy Commencement Speaker, 2006
- Clinical Pharmacist of the Year- West Palm Beach Veterans Affairs Medical Center, 2004
- American College of Cardiology
- American College of Clinical Pharmacy (ACCP)
- American Heart Association
- Evaluation of formulary initiatives/conversions from an efficacy, safety and economic standpoint
- Impact of clinical pharmacy specialists on cardiovascular risk factors
- Use of biomarkers and/or non-invasive hemodynamics to guide antihypertensive therapy
- Chronotherapy, blood pressure variability and 24 hour ambulatory blood pressure monitoring
Heart failure; Hypertension; Atrial fibrillation; Non-invasive measurement of hemodynamics; 24 hour ambulatory blood pressure monitoring; Cardiovascular risk factor modification
Clinical Experience Statement
I approach the management of cardiovascular disease in any given patient with the intent of both preserving the autonomy of the patient while providing them with appropriate evidence based recommendations. My care focuses heavily not only on the provision evidence based pharmacotherapy, but also on assuring the patient has a clear understanding of what their medication regimen can and cannot provide, as well as their role in optimizing their cardiovascular health. I currently practice full-time
- Valencia D, Spoutz P, Stoppi J, Kibert JL, Allen A, Parra D, Hough A. Impact of a Direct Oral Anticoagulant Population Management Tool on Anticoagulation Therapy Monitoring in Clinical Practice. Annals of Pharmacotherapy. 2019; https://doi.org/10.1177/1060028019835843
- Khazan E, Hough A, Parra D, Groppi J. Evaluation of Interventions by Clinical Pharmacy Specialists in Cardiology at a VA Ambulatory Cardiology Clinic. Fed Pract. 2019; 36:56-62.
- Wen Y, Hough A, Parra D, Straka R. Consensus Document on Improving Hypertension Management in Asian Patients. Pharmacotherapy Updates, 2 December 2019. McGraw-Hill, 2019. AccessPharmacy. https://accesspharmacy.mhmedical.com/updatesConten...
- Hough A, Ya-Feng W, Cave B, Parra D, Straka RJ. Hypertension. In: Chisholm-Burns, Schwinghammer, Wells, DiPiro, Kolesar and Malone eds. Pharmacotherapy Principles and Practice. 5th Edition. Columbus OH: McGraw-Hill Companies Inc.; 2019: Chapter 5.
- Minichiello T, Parra D, Barnes G, Allen A. Roundtable Discussion: Anticoagulation Management. Federal Practitioner 2017; November: S4-S10.
- Khazan E, Anastasia E, Hough A, Parra D. Pharmacist-managed Ambulatory Blood Pressure Monitoring Service. Am J Health Syst Pharm 2017; 74(4):190-195.
- Parra D, Hough A. Male with Priority of Ischemic Stroke Reduction. In: Anticoagulation Therapy: Cases and Clinical Correlation, Kiser K ed., Springer International Publishing AG, 15-18, 2017
- Brenner M, Parra D. Patient with Prior History of GI Hemorrhage. In: Anticoagulation Therapy: Cases and Clinical Correlation, Kiser K ed., Springer International Publishing AG, 25-30, 2017
- Brenner M, Parra D. Concerns with Anticoagulant Adherence. In: Anticoagulation Therapy: Cases and Clinical Correlation, Kiser K ed., Springer International Publishing AG, 37-42, 2017.
- Hough A, Parra D. Patient with Concomitant Aortic Valve Stenosis. In: Anticoagulation Therapy: Cases and Clinical Correlation, Kiser K ed., Springer International Publishing AG, 87-92, 2017.
- Hager K, Anastasia E, Parra D. Uncontrolled Hypertension. In Schwinghammer, Wells, DiPiro, Kolesar and Malone eds. Pharmacotherapy Principles & Practice Study Guide: A Case Based Care Plan Approach. 4th Edition. Columbus OH: McGraw-Hill Companies Inc.; 2017: Chapter 3.
- Parra D, Roman Y, Anastasia E, Straka RJ. Hypertension. In: Chisholm-Burns, Schwinghammer, Wells, DiPiro, Kolesar and Malone eds. Pharmacotherapy Principles and Practice. 4th Edition. Columbus OH: McGraw-Hill Companies Inc.; 2016: Chapter 5.
- Long J, Parra D. Reducing Cardioembolic Risk in the Patient with Atrial Fibrillation. Evidence-Based Care of the Patient with Atrial Fibrillation: A Call to Action for Nurses and Advanced Practice Nurses. Monthly Prescribing Reference (MPR). 2015. Available at http://www.empr.com/atrial-fibrillation/section/44...
- Anastasia EJ, Rosenstein RS, Bergsman JA, Parra D. Use of Apixaban After Development of Suspected Rivaroxaban-induced Hepatic Steatosis; A Case Report. Blood Coagul Fibrinolysis. 2015 Sep;26(6):699-702.
- Hager KD, Aronson BD, Smith RC, Parra D, Swanoski M. Improving Blood Pressure Control in Over-the-Road Truck Drivers: Is Provision of Medication Therapy Management by Pharmacists Feasible? Innovations in Pharmacy. 2015;6(1): Article 193 (11 pages) available at http://z.umn.edu/INNOVATIONS
- Parra D, Hough A. Current Therapeutic Approaches to Cardio-Protection in Hypertension. Current Hypertension Reports. 2014;16(8): Article 457 pp 1-12.
- Straka RJ, Parra D, Kaiser S. Hypertension. In: Chisholm-Burns, Schwinghammer, Wells, DiPiro, Kolesar and Malone eds. Pharmacotherapy Principles and Practice. 3rd Edition. Columbus OH: McGraw-Hill Companies Inc.; 2013: Chapter 5.
- Shah S, Coakley C, Hough A, Parra D. Plasma Renin Activity Testing to Guide Triple Antirenin System Drug Therapy in a Patient with Difficult-to-treat Hypertension. Ann Pharmacother 2013; Nov;47(11):1562-8.
- Coakley C, Hough A, Dwyer D, Parra D. Clinical Video Telehealth in a Cardiology Pharmacotherapy Clinic. Am J Health Syst Pharm. 2013 Nov 15;70(22):1974-5.Olson N, DeJongh B, Hough A, Parra D. Plasma Renin Activity-Guided Strategy for the Management of Hypertension. Pharmacotherapy 2012;32(5):446-455.
- Karimi S, Hough A, Beckey C, Parra D. Safety Initiative for Patients on Concomitant Amiodarone and Simvastatin Therapy. Journal of Managed Care Pharmacy 2010;16(7):472-81.
- Segarra-Newnham, Parra D, Martin-Cooper E. Effectiveness and Hepatotoxicity of Statins in Men Seropositive for Hepatitis C Virus. Pharmacotherapy 2007;27(6):845-851.
- Parra D, Beckey N, Stevens G. The Effect of Acetaminophen on the International Normalized Ratio (INR) in Patients Stabilized on Warfarin Therapy. Pharmacotherapy 2007;27(5):675-683.
- Parra D, Beckey N, Raval H, Schnacky K, Calabrese V, Coakley R, Goodhope R. Effect of Splitting Simvastatin Tablets for Control of Low-Density Lipoprotein Cholesterol. American Journal of Cardiology 2005; 95(12): 1481-1483.
- Parra D, Lundy A, Bierman B. Alpha-blocker Monotherapy and Anticipated Occurrences of Heart Failure in Hypertensive Veterans. American Journal of Hypertension 2005; 18(4):574-575.
- Parra D, Legreid AM, Beckey NP, Reyes S. Metformin Monitoring and Change in Serum Creatinine in Patients Undergoing Radiologic Procedures Involving the Administration of Intravenous Contrast Media. Pharmacotherapy 2004;24(8):987-993. Erratum in: Pharmacotherapy 2004; Oct;24(10):1489.
- Geber J, Parra D, Beckey NP, Korman L. Optimizing Drug Therapy in Patients with Cardiovascular Disease: The Impact of Pharmacist-Managed Pharmacotherapy Clinics in a Primary Care Setting. Pharmacotherapy 2002; 22(6):738-47.
- Parra D, Beckey NP, Korman L. Retrospective Evaluation of the Conversion of Amlodipine to Alternative Calcium Channel Blockers. Pharmacotherapy 2000;20(9):1072-1078.
- Beckey NP, Parra D, Colon A. Retrospective Evaluation of a Potential Interaction Between Azithromycin and Warfarin in Patients Stabilized on Warfarin Therapy. Pharmacotherapy 2000;20(9):1055-1059.
- Beckey NP, Korman L, Parra D. Effect of the Moderate Consumption of Olestra in Patients Receiving Long-term Warfarin Therapy. Pharmacotherapy 1999;19(9):1075-1079